Meeting
2011 ASCO Annual Meeting
TEMOBIC: A ANOCEF phase II study of BCNU and temozolomide (TMZ) combination prior to radiotherapy (RT) in anaplasic oligodendroglial gliomas (AOG).
Authors
O. L. Chinot
University Hospital Timone, Marseille, France
O. L. Chinot , K. Hoang-Xuan , M. Fabbro , L. Taillandier , J. Honnorat , M. Barrie , M. Sanson , C. Kerr , P. Beauchesne , S. Cartalat-Carel , D. Autran , A. Loundou , R. Guillevin , K. Mokhtari , D. Figarella-Branger , J. Delattre
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
RECF0443
Citation
J Clin Oncol 29: 2011 (suppl; abstr 2034)
Abstract #
2034
Poster Bd #
23
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Efficacy and safety of radiotherapy (RT) plus temozolomide (TMZ) in elderly patients (EP) with glioblastoma (GBM).
First Author: Giuseppe Lombardi
Poster
2014 ASCO Annual Meeting
Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients (pts) with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric): Results of an Australian phase II clinical trial.
First Author: Mustafa Khasraw
Poster
2014 ASCO Annual Meeting
Phase II trial of vorinostat (VOR) combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (Alliance N0874/ABTC-0902).
First Author: Evanthia Galanis
Poster
2012 ASCO Annual Meeting
Phase II trial of dose-dense temozolomide as initial treatment for progressive low-grade oligodendroglial tumors: A multicentric study of the Italian Association of Neuro-Oncology (AINO).
First Author: Roberta Ruda